Dr. Jen Rogers on the Use of CB-CAPs to Assess Disease Activity in SLE

What is the Type 1 vs Type 2 Lupus Model? How does it shape the care and management of lupus patients? And what impact does it have on the future of drug development to address Type 2 symptoms?

Join Exagen and Dr. Jen Rogers, Director of the Duke Lupus Clinic as she breaks down the abstract, The Use of Cell-bound Complement Activation Product to Assess Disease Activity in SLE, how the study came to be, and its clinical importance to both providers and patients.